RE:Given time investors will connect the dots...
wildbird1 wrote: It is not easy for most peoples(including me) to understand the process of TLT cancer treatment.
Let's resume.
-TLT cancer treatment has a high CR ratio(complete Response) could easily be well over 70%
(70 % is huge).
-TLT cancer treatment has a very low toxicity.
-TLT cancer treatment has a memory response..meaning after the cancer treatment is completed, the patients own immune system start killing cancer cells on it's own.
The three above statements taken alone do not seem much, but taken together it does mean that TLT cancer treatment will be able to treat cancer patients with a weakened immune system, or patients that do not respond to Chemotherapy, or patients that do not respond to Radiation Therapy, and finally treat patients that do not respond to BCG treatment.
That is a lot's of patients.
And the most interesting fact is that TLT cancer treatment doesn't target a very specific cancer cells(like prostate cancer cells), no TLT cancer treatment will target any cancer cells from any cancer(Lung, Brain....).
Valuation...
Once TLT prove that its treatment can cure Prostate cancer, investors will connect the dots and will price the SP value on the many cancer TLT treatment will be able to cure.
The low SP is annoying for now, we just need a little more patience and we will be rewarded big time very soon.
The versatile structural chemistry of this metallic compound gives it a big advantage over other conventional therapies (I.e. chemo, radiation, etc...) that have a single molecular target (I.e. DNA), which makes these therapies so toxic to our healthy cells.
A little structural tinkering of our compound (I.e. changing the ligand attached to the Ruthenium, Osmium, or other base) has the potential to not only enable more precise & more cancer-specific targeting, but also enhance its mechanism of action against "multiple" molecular targets within a cancer cell...while leaving healthy cells intact. Imo, the days of using toxic platinum-based chemo (I.e. Cisplatin) as a stand-alone drug option are numbered.
As for the current sp activity, it is meaningless & should be ignored as it obviously doesn't accurately reflect where we currently stand with our CRs in this pivotal phase...upon which a determination for drug approval will be based.